期刊
BRITISH JOURNAL OF CANCER
卷 109, 期 4, 页码 827-835出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2013.416
关键词
next-generation sequencing; cancer genome analysis
类别
资金
- Wellcome Trust [090532] Funding Source: Medline
- Cancer Research UK [16459] Funding Source: researchfish
Next-generation sequencing (NGS) of cancer genomes promises to revolutionise oncology, with the ability to design and use targeted drugs, to predict outcome and response, and to classify tumours. It is continually becoming cheaper, faster and more reliable, with the capability to identify rare yet clinically important somatic mutations. Technical challenges include sequencing samples of low quality and/or quantity, reliable identification of structural and copy number variation, and assessment of intratumour heterogeneity. Once these problems are overcome, the use of the data to guide clinical decision making is not straightforward, and there is a risk of premature use of molecular changes to guide patient management in the absence of supporting evidence. Paradoxically, NGS may simply move the bottleneck of personalised medicine from data acquisition to the identification of reliable biomarkers. Standardised cancer NGS data collection on an international scale would be a significant step towards optimising patient care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据